{"id":"immediate-release-aspirin-tablets","safety":{"commonSideEffects":[{"rate":"1–3","effect":"Gastrointestinal bleeding or ulceration"},{"rate":"5–10","effect":"Dyspepsia"},{"rate":"2–5","effect":"Nausea"},{"rate":"1–2","effect":"Hemorrhage (minor)"},{"rate":null,"effect":"Allergic reactions (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin acetylates serine residues on COX-1 and COX-2, preventing the synthesis of prostaglandins and thromboxane A2. This reduces platelet activation and aggregation, thereby decreasing thrombotic events, and also provides anti-inflammatory and analgesic effects through reduced prostaglandin production in tissues.","oneSentence":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:19.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)"},{"name":"Pain and fever relief"},{"name":"Inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT04464070","phase":"EARLY_PHASE1","title":"Pathways of Eicosanoid Metabolism","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University","startDate":"2020-08-15","conditions":"Metabolism of Prostaglandin D2","enrollment":10},{"nctId":"NCT05055752","phase":"PHASE1","title":"Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.","status":"COMPLETED","sponsor":"PLx Pharma","startDate":"2020-05-07","conditions":"Bioequivalence","enrollment":24},{"nctId":"NCT01515657","phase":"PHASE3","title":"Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients","status":"COMPLETED","sponsor":"PLx Pharma","startDate":"2012-01","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT00961350","phase":"PHASE3","title":"A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Gastric Ulcer","enrollment":530},{"nctId":"NCT00960869","phase":"PHASE3","title":"Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Gastric Ulcer","enrollment":519},{"nctId":"NCT00995410","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers","status":"COMPLETED","sponsor":"POZEN","startDate":"2009-10","conditions":"Aspirin-Associated Gastric Ulcers","enrollment":380},{"nctId":"NCT02273505","phase":"PHASE1","title":"Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT01557335","phase":"PHASE1","title":"A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540","status":"COMPLETED","sponsor":"POZEN","startDate":"2010-11","conditions":"Platelet Aggregation","enrollment":30},{"nctId":"NCT01015729","phase":"PHASE1","title":"Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Peptic Ulcer Disease","enrollment":30},{"nctId":"NCT00998075","phase":"PHASE1","title":"Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Peptic Ulcer Disease","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Immediate-Release Aspirin Tablets","genericName":"Immediate-Release Aspirin Tablets","companyName":"PLx Pharma","companyId":"plx-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation. Used for Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke), Pain and fever relief, Inflammatory conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}